Bimatoprost Eye System Reduced Pressure in Trial
A new drug-eluting lens system achieved significant intraocular pressure reduction in glaucoma and hypertension patients.
Updated on Oct. 11, 2026 in Biotech
Live Poll
Would you choose a surgical implant over daily eye drops to manage chronic glaucoma?
The Bimatoprost Drug Pad-IOL System successfully reduced intraocular pressure by 35 percent in a 104-patient clinical trial. Participants in the higher-dose group showed a 98 percent medication-free rate at 12 months.
Why it matters
This system aims to eliminate the need for daily eye drops by delivering medication continuously through pads attached to the intraocular lens. The device provides a long-term treatment option during routine cataract surgery.
The system utilizes two drug-eluting pads attached to an intraocular lens to deliver bimatoprost. Patients maintained a best-corrected distance visual acuity of 20/32 or better with endothelial cell loss rates comparable to routine surgery.
The players
AAO Annual Meeting
This is the annual convention hosted by the American Academy of Ophthalmology for vision science professionals.
The details
The device is implanted directly into the capsular bag to manage open-angle glaucoma or ocular hypertension. By automating drug delivery, the technology seeks to provide at least three years of treatment from a single surgical procedure.
Timeline
October 9-12, 2026: Interim trial results were presented at the AAO Annual Meeting.
12 months: Mean intraocular pressure reduction and medication-free rates were recorded.
The Tech Race
This development represents a major shift toward replacing daily medication regimens with sustained-release implants. It competes against traditional topical treatments by offering a passive delivery method that avoids the common issue of patient non-compliance.
Patients undergoing cataract surgery may eventually avoid the burden of daily drop regimens for glaucoma management. The device minimizes user error and ensures consistent medication delivery without requiring lifestyle adjustments after recovery.
The takeaway
This technology demonstrates that intraocular lenses can serve as effective platforms for continuous drug administration. Future research will confirm if the system can successfully reach the goal of three years of treatment from one procedure.
Further reading
Learn more about the latest developments in Biotech.
Source note: This article includes information reported by Ajmc.
Live Poll
Would you choose a surgical implant over daily eye drops to manage chronic glaucoma?
